MediPoint: Breast Cancer Imaging - EU Analysis and Market Forecasts


#168763

266pages

GlobalData

$ 4450

In Stock

 

MediPoint: Breast Cancer Imaging EU Analysis and Market Forecasts

 

Summary

 

Breast cancer is the most common form of cancer in women in both the developed and developing world, but is a rare disease in men. The global incidence of breast cancer is increasing due to an increased lifespan and increasing adoption of western lifestyle risk factors. Early diagnosis of breast cancer is the foundation for increasing survival rates and diagnostic imaging is the most widely used technique to achieve early detection, making diagnostic imaging a cornerstone of breast cancer control.

 

The EU breast cancer imaging market is a mature industry with complex dynamics. The dynamics of this industry vary greatly from one country to another. Therefore, it is essential to examine the market opportunities and barriers that are specific to each region. This report provides an in-depth review of the evolving technologies and the regulatory landscape in the breast cancer screening markets in the EU countries.

 

Scope

 

  • An overview of breast cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized EU Breast cancer imaging market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
  • Investigation of current and future market competition for Breast cancer imaging
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Breast cancer imaging sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as radiologists

 

Reasons to buy

 

  • Understand the trends shaping and driving the EU Breast cancer imaging Market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the EU Breast cancer imaging Market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the markets device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • Whats the next big thing in EU Breast cancer imaging market landscape? Identify, understand and capitalize.

Table of Contents

 

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 13
1.2 List of Figures 18

 

2 Introduction 21
2.1 Catalyst 21
 

3 Disease Overview 22
3.1 Anatomy & Physiology of the Breast 22
3.2 Pathophysiology of Breast Cancer 23
3.3 Detection of Breast Cancer 23
3.4 Types of Breast Cancer 24
3.5 Clinical Presentation 26
3.6 Clinical Outcomes 27
3.6.1 Assessment Procedure 27
3.6.2 Screening Guidelines 30
3.7 Epidemiology of Breast Cancer 31
3.8 Economic Impact of Breast Cancer Imaging 34
 

4 Imaging Techniques 35
4.1 Mammography 35
4.1.1 Overview 35
4.1.2 Types of Mammography 37
4.2 Non-Mammographic Techniques 42
4.2.1 Breast Ultrasound Imaging 42
4.2.2 Breast Magnetic Resonance Imaging 43
4.3 Comparison of Mammography, Ultrasound, and MRI 44
4.4 Alternative Breast Imaging Techniques 45
4.4.1 Nuclear Imaging Techniques 46
4.4.2 Computed Tomography 47
4.4.3 Optical Breast Imaging 48
4.4.4 Electric Impedance-Based Techniques 48
4.4.5 Thermography 49
4.4.6 Elastography 49
4.4.7 Ductogram 49
 

5 Competitive Assessment 50
5.1 Overview 50
5.2 Film Screen Mammography 51
5.2.1 Performa (GE Healthcare) 51
5.2.2 Alpha RT/Alpha ST (GE Healthcare) 53
5.2.3 MAMMOMAT 1000 (Siemens Healthcare) 56
5.2.4 MAMMOMAT 3000 Nova (Siemens Healthcare) 58
5.2.5 M-IV/M-IV Platinum (Hologic) 60
5.2.6 MammoDiagnost (Philips Healthcare) 62
5.2.7 Planmed Nuance Classic (Planmed) 64
5.2.8 Planmed Sophie Classic (Planmed) 66
5.2.9 Analog Giotto Image (Internazionale Medico Scientifica) 68
5.2.10 HAWK-2M (Hologic) 70
5.2.11 MGU-1000A (Toshiba Medical Systems) 72
5.3 CR Mammography 74
5.3.1 Fuji Computed Radiography Mammography Suite (FCRMS) (Fujifilm Medical Systems) 74
5.3.2 KODAK DirectView (Carestream Health) 77
5.3.3 Xpress CR System (Konica Minolta) 79
5.3.4 REGIUS PureView (Konica Minolta) 81
5.3.5 Agfa CR Mammography Systems (DX-M, CR 30-Xm, and CR 85-X) (Agfa Healthcare) 83
5.4 Full-Field Digital Mammography 85
5.4.1 Selenia Dimensions (Hologic) 86
5.4.2 Selenia (Hologic) 89
5.4.3 Selenia S (Hologic) 91
5.4.4 Selenia Performance (Hologic) 93
5.4.5 Senographe DS (GE Healthcare) 95
5.4.6 Senographe Essential (GE Healthcare) 97
5.4.7 Senographe Care (GE Healthcare) 100
5.4.8 SenoBright CESM (GE Healthcare) 102
5.4.9 MAMMOMAT Inspiration (Siemens Healthcare) 104
5.4.10 Aspire HD (US)/Amulet (Outside the US) (Fujifilm) 106
5.4.11 MammoDiagnost DR (Philips Healthcare) 108
5.4.12 MicroDose (Philips Healthcare) 110
5.4.13 Giotto Image 3D/3DL (Internazionale Medico Scientifica) 112
5.4.14 Planmed Nuance/Nuance Excel (Planmed) 114
5.4.15 Fairy DR (Allengers Medical Systems) 116
5.4.16 Serenity 118
5.5 3D Mammography 120
5.5.1 Selenia Dimensions 3D System (Hologic) 120
5.5.2 GE Breast Tomosynthesis (GE Healthcare) 122
5.5.3 True 3D Breast Tomosynthesis (Siemens Healthcare) 124
5.5.4 Giotto Tomo (Internazionale Medico Scientifica) 126
5.5.5 FUJIFILM 3Dimensional Mammography (Fujifilm) 128
5.6 Breast Ultrasound Imaging 130
5.6.1 somo.v Automated Breast Ultrasound (ABUS) (GE Healthcare) 130
5.6.2 SonoCine AWBUS (SonoCine) 132
5.6.3 ACUSON S2000 ABVS (Siemens Healthcare) 134
5.6.4 Terason t3200 Ultrasound System Breast Series (Terason Ultrasound) 136
5.7 Breast MRI 138
5.7.1 Aurora 1.5T Dedicated Breast MRI System (Aurora Imaging Technology) 138
5.8 Other Breast Imaging Techniques 140
5.8.1 PEM Flex Solo II (Naviscan) 140
5.8.2 Computerized Tomography Laser Mammography (CTLM) Model 1020 (Imaging Diagnostic Systems) 142
5.8.3 Dilon 6800/Dilon 6800 Acella (Dilon Diagnostics) 144
5.8.4 LumaGEM (Gamma Medica) 146
5.8.5 Discovery NM 750b (GE Healthcare) 148
 

6 Unmet Needs 150
6.1 Lower Radiation Dose 150

6.2 Increase Patient Comfort 152
6.3 Reduce False-Positives and False-Negatives 153
6.4 Loss of Sensitivity of Mammography in Dense Breasts 155
6.5 Unreliable Mammograms in Surgically-Operated Breasts and Breasts with Implants 157
6.6 Commitment to Training 158
 

7 Pipeline Products 160
7.1 Breast Cancer Imaging Pipeline Products Overview 160
7.2 MAMMOMAT Inspiration PRIME Edition 161
7.2.1 Overview 161
7.2.2 SWOT Analysis 161
7.3 MicroDose SI 162
7.3.1 Overview 162
7.3.2 SWOT Analysis 162
7.4 Selenia Dimensions 2D Contrast-Enhanced Digital Mammography (CEDM) 163
7.4.1 Overview 163
7.4.2 SWOT Analysis 163
7.5 SenoCase 164
7.5.1 Overview 164
7.5.2 SWOT Analysis 165
7.6 Electrical Mammogram 166
7.6.1 Overview 166
7.6.2 SWOT Analysis 166
 

8 Industry Overview 167
8.1 Purchasing Cycle 167
8.1.1 Product Life Cycle 167
8.1.2 Cost Effectiveness in Screening Settings 169
8.1.3 Cost-Effectiveness in Diagnostic Settings 169
8.2 Market Access 170
8.2.1 Purchasing Decisions 170
8.2.2 Regulatory Process 171
8.3 Quality Assurance 172
8.4 Adoption of New Technologies 173
8.4.1 Influence of Clinical Trials Results 173
8.4.2 Reimbursement 174
8.4.3 Economic Resources 174
8.4.4 Competitive Advantage 175
8.5 Current Reimbursement Trends 176
8.5.1 France 176
8.5.2 Germany 177
8.5.3 Italy 177
8.5.4 Spain 177
8.5.5 UK 177
8.6 Trends in Detector Technology for Digital Mammography 178
8.7 Evolving Scatter-Removal Mechanisms 182
8.8 Overdiagnosis 184
8.9 Malpractice Litigations 185
8.10 Mergers and Acquisitions/Key Partnerships 186
8.10.1 GE Healthcare Acquires U-Systems 186
8.10.2 Koninklijke Philips Electronics Acquires MicroDose Mammography from Sectra 186
8.10.3 Hologic Acquires Beijing Healthcome Technology 186
8.10.4 Hologic Acquires Sentinelle Medical 186
8.10.5 Koninklijke Philips Electronics Acquires Shanghai Apex Electronics Technology 187
8.10.6 Fujifilm Medical Systems acquired FUJIFILM-RU 187
8.10.7 Other Key Events 187
 

9 Current and Future Players 188
9.1 Overview 188
9.2 Trends in Corporate Strategy 189
9.3 Company Profiles 190
9.3.1 GE Healthcare 190
9.3.2 Hologic 192
9.3.3 Siemens 194
9.3.4 Koninklijke Philips Electronics 195
9.3.5 Fujifilm Medical Systems 197
9.3.6 Internazionale Medico Scientifica (IMS) 198
9.3.7 Planmed 199
9.3.8 Konica Minolta Medical Imaging 200
9.3.9 Agfa Healthcare 201
9.3.10 Carestream Health 202
9.3.11 SonoCine 203
9.3.12 Aurora Imaging Technology 204
9.3.13 Imaging Diagnostic Systems 205
9.3.14 Naviscan 207
9.3.15 Dilon Diagnostics 208
9.3.16 Gamma Medica 209
9.3.17 Allengers Medical Systems 210
 

10 Market Drivers & Opportunities 211
10.1 Market Drivers 211

10.1.1 Increase in the Incidence of Breast Cancer 211
10.1.2 Increased Awareness of the Benefits of Screening 211
10.1.3 Increased Breast Cancer Incidence Due to an Aging Population 212
10.1.4 New Technologies to Drive Market Growth 212
10.1.5 Changes in Age Inclusion Criteria in Breast Cancer Screening Programs 213
10.1.6 Adoption of Tomosynthesis in Europe 214
10.2 Opportunities 215
10.2.1 Invest in Emerging Technologies 215
10.2.2 Product Improvement 216
10.3 Market Barriers 217
10.3.1 Shortage of Dedicated Mammography Professionals 217
10.3.2 Reduced Hospital Budgets 217
10.3.3 Refurbished Equipment Sales 218
10.3.4 Reimbursement 218
10.3.5 Substitutes 219
 

11 Country Outlooks & Forecasts 220
11.1 EU Markets Overview 220
11.2 France 222
11.2.1 France Market Analysis 222
11.3 Germany 223
11.3.1 Germany Market Analysis 223
11.4 Italy 224
11.4.1 Italy Market Analysis 224
11.5 Spain 225
11.5.1 Spain Market Analysis 225
11.6 United Kingdom 226
11.6.1 United Kingdom Market Analysis 226
 

12 Appendix 228
12.1 Bibliography 228
12.2 Abbreviations 255
12.3 Report Methodology 259
12.3.1 Overview 259
12.3.2 Coverage 259
12.3.3 Secondary Research 259
12.3.4 Forecast Methodology 260
12.4 Physicians and Specialists Included in this Study 261
12.5 Primary Research 262
12.6 Physician Survey 262
12.7 About the Authors 263
12.7.1 Analysts 263
12.7.2 Global Head of Healthcare 264
12.8 Definitions 265
12.9 About MediPoint 265
12.10 About GlobalData 265
12.11 Contact Us 266
12.12 Disclaimer 266

 

Table 1: Breast Cancer Types, Including Diagnostic Procedures 25

Table 2: ACR Breast Imaging Reporting and Database System (BI-RADS) 27

Table 3: Selected Breast Cancer Incidence Rates, 2002 32

Table 4: Comparison of Mammography, Ultrasound, and MRI for Breast Imaging 44

Table 5: Performa Product Profile 52

Table 6: Performa SWOT Analysis 52

Table 7: Alpha RT/Alpha ST Product Profile 54

Table 8: Alpha RT/Alpha ST SWOT Analysis 55

Table 9: MAMMOMAT 1000 Product Profile 57

Table 10: MAMMOMAT 1000 SWOT Analysis 57

Table 11: MAMMOMAT 3000 Nova Product Profile 59

Table 12: MAMMOMAT 3000 Nova SWOT Analysis 59

Table 13: M-IV/M-IV Platinum Product Profile 61

Table 14: M-IV/M-IV Platinum SWOT Analysis 61

Table 15: MammoDiagnost Product Profile 63

Table 16: MammoDiagnost SWOT Analysis 63

Table 17: Planmed Nuance Classic Product Profile 65

Table 18: Planmed Nuance Classic SWOT Analysis 65

Table 19: Planmed Sophie Classic Product Profile 67

Table 20: Planmed Sophie Classic SWOT Analysis 67

Table 21: Analog Giotto Image Product Profile 69

Table 22: Analog Giotto Image SWOT Analysis 69

Table 23: HAWK-2M Product Profile 71

Table 24: HAWK-2M SWOT Analysis 71

Table 25: MGU-1000A Product Profile 73

Table 26: MGU-1000A SWOT Analysis 73

Table 27: Fuji Computed Radiography Mammography Suite (FCRMS) Product Profile 75

Table 28: Fuji Computed Radiography Mammography Suite (FCRMS) SWOT Analysis 76

Table 29: KODAK DirectView CR System Product Profile 78

Table 30: KODAK DirectView CR System SWOT Analysis 78

Table 31: Xpress CR System Product Profile 79

Table 32: Xpress CR System SWOT Analysis 80

Table 33: REGIUS PureView Product Profile 82

Table 34: REGIUS PureView SWOT Analysis 82

Table 35: Agfa CR Mammography Systems (DX-M, CR 30-Xm, and CR 85-X) Product Profile 84

Table 36: Agfa CR Mammography Systems (DX-M, CR 30-Xm, and CR 85-X) SWOT Analysis 84

Table 37: FFDM SWOT Analysis 85

Table 38: Selenia Dimensions Product Profile 87

Table 39: Selenia Dimensions SWOT Analysis 88

Table 40: Selenia Product Profile 90

Table 41: Selenia SWOT Analysis 90

Table 42: Selenia S Product Profile 92

Table 43: Selenia S SWOT Analysis 92

Table 44: Selenia Performance Product Profile 94

Table 45: Selenia Performance SWOT Analysis 94

Table 46: Senographe DS Product Profile 96

Table 47: Senographe DS SWOT Analysis 96

Table 48: Senographe Essential/Senographe Essential E Product Profile 98

Table 49: Senographe Essential SWOT Analysis 99

Table 50: Senographe Care Product Profile 101

Table 51: Senographe Care SWOT Analysis 101

Table 52: SenoBright CESM Product Profile 103

Table 53: SenoBright CESM SWOT Analysis 103

Table 54: MAMMOMAT Inspiration Product Profile 105

Table 55: MAMMOMAT Inspiration SWOT Analysis 105

Table 56: Aspire HD/Amulet Product Profile 107

Table 57: Aspire HD/Amulet SWOT Analysis 107

Table 58: MammoDiagnost DR Product Profile 108

Table 59: MammoDiagnost DR SWOT Analysis 109

Table 60: MicroDose Product Profile 111

Table 61: MicroDose SWOT Analysis 111

Table 62: Giotto Image 3D/3DL Product Profile 113

Table 63: Giotto Image 3D/3DL SWOT Analysis 113

Table 64: Planmed Nuance/Nuance Excel Product Profile 115

Table 65: Planmed Nuance/Nuance Excel SWOT Analysis 115

Table 66: Fairy DR Product Profile 117

Table 67: Fairy DR SWOT Analysis 117

Table 68: Serenity Product Profile 119

Table 69: Serenity SWOT Analysis 119

Table 70: Selenia Dimensions 3D System Product Profile 121

Table 71: Selenia Dimensions SWOT Analysis 121

Table 72: GE Breast Tomosynthesis Product Profile 123

Table 73: GE Breast Tomosynthesis SWOT Analysis 123

Table 74: True 3D Breast Tomosynthesis Product Profile 125

Table 75: True 3D Breast Tomosynthesis SWOT Analysis 125

Table 76: Giotto Tomo Product Profile 127

Table 77: Giotto Tomo SWOT Analysis 127

Table 78: FUJIFILM 3Dimensional Mammography Product Profile 129

Table 79: FUJIFILM 3Dimensional Mammography SWOT Analysis 129

Table 80: somo.v ABUS Product Profile 131

Table 81: somo.v ABUS SWOT Analysis 131

Table 82: SonoCine AWBUS Product Profile 133

Table 83: SonoCine AWBUS SWOT Analysis 133

Table 84: ACUSON S2000 ABVS Product Profile 135

Table 85: Acuson S2000 ABVS SWOT Analysis 135

Table 86: Terason t3200 Ultrasound System Breast Series Product Profile 137

Table 87: Terason t3200 Ultrasound System Breast Series SWOT Analysis 137

Table 88: Aurora 1.5T Dedicated Breast MRI System Product Profile 139

Table 89: Aurora 1.5T Dedicated Breast SWOT Analysis 139

Table 90: PEM Flex Solo II Product Profile 141

Table 91: PEM Flex Solo II SWOT Analysis 141

Table 92: Computerized Tomography Laser Mammography (CTLM) Model 1020 Product Profile 143

Table 93: Computerized Tomography Laser Mammography (CTLM) Model 1020 SWOT Analysis 143

Table 94: Dilon 6800/Dilon 6800 Acella Product Profile 145

Table 95: Dilon 6800/Dilon 6800 Acella SWOT Analysis 145

Table 96: LumaGEM Product Profile 147

Table 97: LumaGEM SWOT Analysis 147

Table 98: Discovery NM 750b Product Profile 149

Table 99: Discovery NM 750b SWOT Analysis 149

Table 100: Breast Cancer Imaging Pipeline Products 160

Table 101: MAMMOMAT Inspiration PRIME Edition SWOT Analysis 161

Table 102: Philips MicroDose SI SWOT Analysis 162

Table 103: Selenia Dimensions 2D Contrast Imaging SWOT Analysis 163

Table 104: SenoCase SWOT Analysis 165

Table 105: Electrical Mammogram SWOT Analysis 166

Table 106: Other Key Events in the Breast Cancer Imaging Market 187

Table 107: GE Healthcare SWOT Analysis, 2013 191

Table 108: Hologic SWOT Analysis, 2013 193

Table 109: Siemens SWOT Analysis, 2013 194

Table 110: Koninklijke Philips Electronics SWOT Analysis, 2013 196

Table 111: Fujifilm Medical Systems, SWOT Analysis, 2013 197

Table 112: Internazionale Medico Scientifica SWOT Analysis, 2013 198

Table 113: Planmed, SWOT Analysis, 2013 199

Table 114: Konica Minolta Medical Imaging, SWOT Analysis, 2013 200

Table 115: Agfa Healthcare, SWOT Analysis, 2013 201

Table 116: Carestream Health, SWOT Analysis, 2013 202

Table 117: SonoCine, SWOT Analysis, 2013 203

Table 118: Aurora Imaging Technology, SWOT Analysis, 2013 204

Table 119: Imaging Diagnostic Systems, SWOT Analysis, 2013 206

Table 120: Naviscan, SWOT Analysis, 2013 207

Table 121: Dilon Diagnostics, SWOT Analysis, 2013 208

Table 122: Gamma Medica, SWOT Analysis, 2013 209

Table 123: Allengers Medical Systems, SWOT Analysis, 2013 210

Table 124: Major Events Affecting the EU Breast Cancer Imaging Market, 2011-2018 220

Table 125: Sales Forecasts for Breast Cancer Imaging in the EU Markets, 2009–2018 220

Table 126: Sales Forecasts for Breast Cancer Imaging in France, 2009–2018 222

Table 127: Sales Forecasts for Breast Cancer Imaging in Germany, 2009–2018 223

Table 128: Sales Forecasts for Breast Cancer Imaging in Italy, 2009–2018 224

Table 129: Sales Forecasts for Breast Cancer Imaging in Spain, 2009–2018 225

Table 130: Sales Forecasts for Breast Cancer Imaging in the UK, 2009–2018 226

Table 131: Physicians Surveyed, By Country 262


Figure 1: Anatomy of the Breast 22
Figure 2: Breast Cancer Screening, Diagnostic Evaluation, and Follow-Up 28
Figure 3: Percentage Use of Ultrasound Imaging and MRI for Breast Cancer Screening and Follow-Up, 20092016 29
Figure 4: Breast Cancer Risk Factors 31
Figure 5: Average EU Breast Cancer Incidence, CAGR, 20122018 33
Figure 6: Projected EU Breast Cancer Incidence, 20122018 33
Figure 7: Comparison Between Digital (FFDM) and Analog (FSM) Mammography 38
Figure 8: Use of Alternative Breast Imaging Modalities, 20092016 45
Figure 9: Performa 51
Figure 10: Alpha RT 53
Figure 11: Alpha ST 54
Figure 12: MAMMOMAT 1000 56
Figure 13: MAMMOMAT 3000 Nova 58
Figure 14: M-IV/M-IV Platinum 60
Figure 15: MammoDiagnost 62
Figure 16: Planmed Nuance Classic 64
Figure 17: Planmed Sophie Classic 66
Figure 18: Analog Giotto Image 68
Figure 19: HAWK-2M 70
Figure 20: MGU-1000A 72
Figure 21: Aspire CRm 75
Figure 22: KODAK DirectView CR System 77
Figure 23: Xpress CR System 79
Figure 24: REGIUS PureView Type M 81
Figure 25: DX-M Digitizer 83
Figure 26: Selenia Dimensions 86
Figure 27: Selenia 89
Figure 28: Selenia S 91
Figure 29: Selenia Performance 93
Figure 30: Senographe DS 95
Figure 31: Senographe Essential 97
Figure 32: Senographe Care 100
Figure 33: SenoBright CESM* 102
Figure 34: MAMMOMAT Inspiration 104
Figure 35: Aspire HD 106
Figure 36: MammoDiagnost DR 108
Figure 37: MicroDose 110
Figure 38: Giotto Image 3D/3DL 112
Figure 39: Planmed Nuance/Nuance Excel 114
Figure 40: Fairy DR 116
Figure 41: Serenity 118
Figure 42: Selenia Dimensions 2D System 120
Figure 43: Senographe Essential 122
Figure 44: True 3D Breast Tomosynthesis* 124
Figure 45: Giotto Tomo 126
Figure 46: Fujifilm 3D Mammography Viewer 128
Figure 47: somo.v ABUS 130
Figure 48: SonoCine AWBUS 132
Figure 49: ACUSON S2000 ABVS 134
Figure 50: Terason t3200 Ultrasound System Breast Series 136
Figure 51: Aurora 1.5T Dedicated Breast MRI System 138
Figure 52: PEM Flex Solo II 140
Figure 53: CTLM Model 1020 142
Figure 54: Dilon 6800 Acella 144
Figure 55: Dilon 6800 145
Figure 56: LumaGEM 146
Figure 57: Discovery NM 750b 148
Figure 58: Percentage of False-Positive, False-Negative and Accurate Breast Cancer Diagnoses from 20112012 154
Figure 59: SenoCase 164
Figure 60: Product Life Cycle 168
Figure 61: Breast Screening Programs in the EU 176
Figure 62: Detector Evolution 178
Figure 63: Comparison Between a Typical Direct Conversion Detector and a Direct Optical Switching Detector 179
Figure 64: Photon-Counting Detector Technology 181
Figure 65: Linear and High Transmission Cellular Grids 183
Figure 66: Trends in the Use of Mammographic Techniques, 20092016 214
Figure 67: Sales Forecasts for Breast Cancer Imaging in the EU Markets, 20092018 220
Figure 68: Global Breast Cancer Imaging Market Revenue, by Region, 2011 and 2018 221
Figure 69: Sales Forecasts for Breast Cancer Imaging in France, 20092018 222
Figure 70: Sales Forecasts for Breast Cancer Imaging in Germany, 20092018 223
Figure 71: Sales Forecasts for Breast Cancer Imaging in Italy, 20092018 224
Figure 72: Sales Forecasts for Breast Cancer Imaging in Spain, 20092018 225
Figure 73: Sales Forecasts for Breast Cancer Imaging in the UK, 2009-2018 226